The humanized monoclonal antibody trastuzumab (Herceptin®, F. Hoffmann-La Roche, Basel, Switzerland) binds to HER2, inhibiting ligand-independent HER2 signaling and promoting antibody-dependent cell-mediated cytotoxicity of HER2-positive cancer cells. This evidence concerns the gene ERBB2 and cancer.